GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioNeutra Global Corp (TSXV:BGA) » Definitions » Debt-to-EBITDA

BioNeutra Global (TSXV:BGA) Debt-to-EBITDA : 1.02 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is BioNeutra Global Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioNeutra Global's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.46 Mil. BioNeutra Global's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$7.18 Mil. BioNeutra Global's annualized EBITDA for the quarter that ended in Dec. 2023 was C$7.50 Mil. BioNeutra Global's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioNeutra Global's Debt-to-EBITDA or its related term are showing as below:

TSXV:BGA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -21.71   Med: -0.75   Max: 17.68
Current: -21.71

During the past 13 years, the highest Debt-to-EBITDA Ratio of BioNeutra Global was 17.68. The lowest was -21.71. And the median was -0.75.

TSXV:BGA's Debt-to-EBITDA is ranked worse than
100% of 1431 companies
in the Consumer Packaged Goods industry
Industry Median: 2.12 vs TSXV:BGA: -21.71

BioNeutra Global Debt-to-EBITDA Historical Data

The historical data trend for BioNeutra Global's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNeutra Global Debt-to-EBITDA Chart

BioNeutra Global Annual Data
Trend Feb14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.75 -4.72 -6.18 -5.15 -21.71

BioNeutra Global Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.34 -3.45 -2.04 -2.01 1.02

Competitive Comparison of BioNeutra Global's Debt-to-EBITDA

For the Packaged Foods subindustry, BioNeutra Global's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNeutra Global's Debt-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioNeutra Global's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioNeutra Global's Debt-to-EBITDA falls into.



BioNeutra Global Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioNeutra Global's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.463 + 7.177) / -0.352
=-21.70

BioNeutra Global's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.463 + 7.177) / 7.5
=1.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


BioNeutra Global  (TSXV:BGA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BioNeutra Global Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioNeutra Global's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNeutra Global (TSXV:BGA) Business Description

Traded in Other Exchanges
Address
9608 - 25 Avenue NW, Edmonton, AB, CAN, T6N 1J4
BioNeutra Global Corp is engaged in the research, development, production, and commercialization of food ingredients for neutraceutical, functional and mainstream foods, focusing on oligosaccharides. Its product portfolio provides ingredients for various food systems, that contribute to human nutrition and wellness in functional and healthy foods. Its prime product, VitaFiber IMO, is offered in both powder and syrup form. The company operates in Canada while generating sales revenue from various countries internationally. It has a single industry segment, manufacturing and trading of products. The majority of the revenue is derived from the United States.

BioNeutra Global (TSXV:BGA) Headlines

No Headlines